AptLNP — programmable delivery.
AptLNP is a programmable lipid nanoparticle system that uses AI-designed aptamers as targeting ligands to deliver beyond the liver.
Programmable payloads.
AptLNP carries folded aptamer cargo to tissues other particles never reach — extrahepatic delivery, by design.
Beyond the liver
Traditional lipid nanoparticles (LNPs) tend to accumulate in the liver, limiting their broader applications. Our innovative aptLNP system transcends this limitation by incorporating a proprietary targeting layer that directs LNPs to specific, extrahepatic tissues and cell types.
Modular targeting
With aptamers as a modular targeting layer, our aptLNP system seamlessly integrates with existing LNP formulations. Our aptamers can be programmed to bind virtually any cellular receptor, enabling precise delivery to targeted cells. We are advancing a portfolio of aptLNPs designed to selectively target specific cell types — including cancer cells and immune cells — and opening new frontiers in precision medicine.
AI-designed aptamers
Our aptLNP system utilizes AI-designed, cell receptor-specific aptamers as programmable targeting ligands to optimize both affinity and specificity for desired cell targets, while minimizing immunogenicity caused by non-specific protein interactions.
The surfaceome advantage
Recognizing that on-target and off-target cells are often distinguished by complex patterns, such as multiple receptor combinations or subtle expression level differences, aptLNPs leverage the unique "surfaceome" of cells. This capability enables precise delivery by targeting multiple cell surface receptors simultaneously, providing unparalleled accuracy for even the most challenging therapeutic applications.
In-vivo CAR-T
Current ex vivo cell therapies, like therapeutic CAR-T, involve intricate and time-intensive manufacturing processes tailored to each individual patient. Our aptLNP system is designed to revolutionize this approach by enabling the in vivo generation of CAR-T cells. This scalable solution simplifies production for developers and enhances safety and accessibility for patients, paving the way for a new era in cell therapy.
Advantages
No permanent CAR integration
Transient, controlled CAR expression — not a permanent edit.
In-vivo off-the-shelf drug
Manufactured once, dosed in clinic — no patient-specific cell prep.
Repeatable, non-viral dosing
Lipid-based delivery enables repeat administration.
No preconditioning required
Avoid the lymphodepletion regimens conventional CAR-T demands.
Tunable density
Aptamer ligand density on the LNP surface is dialed in per-application — finer control over avidity and specificity.